Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
Age
12–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Had a negative sentinel lymph node biopsy.
Participant has not been previously treated for melanoma.
ECOG 0 or 1.
Participants must have been diagnosed with histologically confirmed, Resected, Stage IIB/C cutaneous melanoma.
You may not be if
History of ocular or mucosal melanoma.
Pregnant or nursing women.
Participants with active known or suspected autoimmune disease.
Known history of allergy or hypersensitivity to study drug components.
Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, anti-CTLA-4 antibody, or agents that target IL-2 pathways, T-cell stimulators, or checkpoint pathways.
Clareo Health | Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma
